James R. Kasinger - 10 Mar 2025 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
General Counsel and Secretary
Signature
/s/ Elizabeth Ryland Waldinger, attorney-in-fact
Issuer symbol
CRSP
Transactions as of
10 Mar 2025
Net transactions value
-$169,242
Form type
4
Filing time
12 Mar 2025, 19:05:05 UTC
Previous filing
19 Feb 2025
Next filing
18 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRSP Common Shares Options Exercise +5,500 +7.3% 80,380 10 Mar 2025 Direct F1
transaction CRSP Common Shares Sale $120,897 -2,850 -3.5% $42.42 77,530 11 Mar 2025 Direct F2
transaction CRSP Common Shares Options Exercise +2,250 +2.9% 79,780 11 Mar 2025 Direct F1
transaction CRSP Common Shares Sale $48,345 -1,116 -1.4% $43.32 78,664 12 Mar 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Restricted Stock Units Options Exercise -5,500 -33% 11,000 10 Mar 2025 Common Shares 5,500 Direct F1, F3
transaction CRSP Restricted Stock Units Options Exercise -2,250 -100% 0 11 Mar 2025 Common Shares 2,250 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F2 Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
F3 This restricted stock unit award was granted on March 10, 2023 with respect to 22,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027.
F4 This restricted stock unit award was granted on March 11, 2021 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025.